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Abstract
Study of P2-purinoceptor subtypes has been difficult due to the lack of potent and selective 
ligands. With the goal of developing high affinity P2-purinoceptor-selective agonists, we have 
synthesized a series of analogues of adenine nucleotides modified on the purine ring as chain-
extended 2-thioethers or as N6-methyl-substituted compounds. Chemical functionality 
incorporated in the thioether moiety included cyanoalkyl, nitroaromatic, amino, thiol, cycloalkyl, 
n-alkyl, and olefinic groups. Apparent affinity of the compounds for P2Y-purinoceptors was 
established by measurement of P2Y-purinoceptor-promoted phospholipase C activity in turkey 
erythrocyte membranes and relaxation of carbachol-contracted smooth muscle in three different 
preparations (guinea pig taenia coil, rabbit aorta, and rabbit mesenteric artery). Activity at P2X-
purinoceptors was established by measurement of contraction of rabbit saphenous artery and of the 
guinea pig vas deferens and urinary bladder. All 11 of the 2-thioethers of ATP stimulated the 
production of inositol phosphates with K0.5 values of 1.5–770 nM, with an (aminophenyl)ethyl 
derivative being most potent. Two adenosine diphosphate analogues were equipotent to the 
corresponding ATP analogues. Adenosine monophosphate analogues were full agonists, although 
generally 4 orders of magnitude less potent. ATP 2-thioethers displayed pD2 values in the range of 
6–8 in smooth muscle assay systems for activity at P2Y-receptors. There was a significant 
correlation for the 2-thioether compounds between the pK0.5 values for inositol phosphate 
production and the pD2 values for relaxation mediated via the P2Y-purinoceptors in the guinea pig 
taenia coli, but not for the vascular P2Y-receptors or for the P2X-receptors. At P2X-receptors, no 
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activity was observed in the rabbit saphenous artery, but variable degrees of activity were 
observed in the guinea pig vas deferens and bladder depending on distal substituents of the 
thioether moiety. N6-Methyl-ATP was inactive at P2X-receptors, and approximately equipotent to 
ATP at taenia coli P2Y-receptors. This suggested that hybrid N6-methyl and 2-thioether ATP 
derivatives might be potent and selective for certain P2Y-receptors, as was shown for one such 
derivative, N6-methyl-2-(5-hexenylthio)-ATP.
Introduction
Extracellular ATP has a role as a fast cotransmitter that is released in conjunction with 
norepinephrine and other transmitters at the neuroeffector junctions of many vascular and 
visceral smooth muscles.1–3 Recently, it was reported that ATP can act as a fast transmitter 
at synapses between neurons in the coeliac ganglion4,5 and in the central nervous system6 
via opening of ligand-gated ion channels.
ATP activates purinergic receptors of the P2-type (P1 designates adenosine receptors with 
A1, A2, etc., subtypes, reviewed in ref 7). Several major categories of P2-receptors have 
been defined8 based on differential potencies of various ATP derivatives. P2X-receptors are 
activated by α,β-methylene-ATP and apparently consist of ligand-gated cation channels.9,10 
P2Y-receptors are activated by 2-(methylthio)-ATP and regulate inositol lipid 
hydrolysis11–15 and possibly other second messenger pathway(s). A less clearly defined 
subtype of the P2-receptor family, the P2U-receptor,16 also promotes inositol lipid hydrolysis 
and is activated by ATP and UTP but not by many analogues of ATP, UTP, and ADP. Other 
cell-specific P2-receptors have been proposed. ADP regulates platelet cell function through 
P2Z-receptors,2,8,17 and P2Z-receptors on mast cells, fibroblasts, and leukocytes regulate ion 
permeability.2,8,17,18
Pharmacological, biochemical, and structural characterization of P2-receptors has been 
relatively limited, and the development of P2-receptor ligands has lagged far behind the 
development of P1-receptor ligands, in part due to the greater difficulties in synthesis and 
purification of nucleoside triphosphates. We have designed a series of new analogues with 
the goal of developing high-affinity, P2Y-receptor-selective, and metabolically stable 
agonists. Several of these already have been shown to be more potent than ATP in raising 
Ca2+ levels via P2Y-like receptors in developing chick myotubes.19 These nucleotides are 
derivatives of 2-(methylthio)-ATP, in which the S-methyl group has been extended to form a 
functionalized chain, for derivatization by the functionalized congener approach.20 The 
selectivity of these and related derivatives of ATP have been established in biochemical12,15 
and smooth muscle2,21 assay systems, and the results emphasize structural features that 
markedly enhance P2Y-receptor potency and selectivity.
Results
Synthesis
Due to its high affinity at P2Y-receptors in binding and functional assays,12,22 it seemed that 
2MeSATP may serve as a good lead structure for new P2Y-agonists. However, 2MeSATP 
Fischer et al. Page 2













has been reported to be hydrolyzed by ectonucleotidases19 under the biochemical assay 
conditions (e.g., 30–35 °C, 20–60 min), which leads to confusion about the nature of the 
biologically active species. This problem was resolved upon the elaboration and elongation 
of the side chain of 2-(alkylthio)-ATP derivatives.19 Those “second generation” ligands 
were highly stable metabolically as indicated by comparison with 2MeSATP and ATP under 
various conditions of incubation with intact and broken cell preparations.19 The increased 
stability is probably due to the steric hindrance by the 2-position chain at the 
ectonucleotidase binding site. Thus, long-chain 2-(alkylthio)-ATP derivatives are lead 
structures which may provide both potency and stability of the ligands.
Our synthetic aim was as follows: (a) Elaboration of the side chain on C-2 by different distal 
substituents, e.g. polar groups, hydrogen-bonding functions, and aromatic rings, thus making 
an additional potential anchor for improving the binding to the receptor. (b) Attaching 
different functional groups that may serve as precursors to labeled ligands or for attachment 
of reporter groups. In similar fashion, the concept of functionalized congeners in the design 
of purines as P1-receptor ligands has been described.20 (c) Combination of 2-thio-substituted 
ATP with other modifications for enhancement of selectivity and potency. (d) Synthesis of 
lower homologues, the corresponding AMP and ADP derivatives for comparison with the 
triphosphates.
Following the above-mentioned guidelines (a) and (b), we synthesized compounds 8–18, 
bearing an alkyl, olefin, or aromatic side chain, some of which are substituted by polar 
groups like cyano or nitro (Table I). A two-step synthesis (Figure 1) of those agonists 
consisted of alkylation of 2-thioadenosine (modified from ref 19) by the appropriate alkyl 
bromide in a dilute NaOH/MeOH solution at 20–50 °C or with triethylamine in DMF, 
followed by a one-pot triphosphorylation.23,24 ATP derivatives were obtained in 14–45% 
yield, and variable amounts of the corresponding AMP derivatives were obtained as well 
(34%–69% yield). The nucleotides were purified on ion-exchange resin columns (DEAE 
A-25 Sephadex) using a 0.4–0.6 M NH4HCO3 buffer gradient. The latter was preferred over 
Et3NH+HCO3−, due to its greater volatility and simpler 1H NMR spectra of the product in 
its ammonium salt form. In some cases further purification on HPLC was required. All the 
derivatives tested for biological activity were characterized by HPLC and and 1H and 31P 
NMR as well as high-resolution FAB spectra, all of which are essential for structure and 
purity determination.
The diphosphate derivative, 10, was synthesized by the same method described above, 
except for using the tributylammonium phosphate salt for condensation with the 
phosphorodichloridate intermediate instead of the corresponding pyrophosphate salt. This 
reaction gave rise not only to 2-(5-hexenylthio)-ADP, 10 (~30% yield), but also to the 
corresponding AMP, 11 (~40% yield), and ATP, 9 (~5% yield), derivatives. The assumed 
mechanism for the formation of the triphosphate is via a cyclic metatriphosphate 
intermediate, which eventually undergoes hydrolysis to the open-chain triphosphate.25,26
Substitution of the side chain with an amino group was intended for attachment of reporter 
groups,20 cross-linking to the receptor, immobilization on a solid matrix for affinity 
chromatography of P2-purinoceptors, or to act as a distal anchor to enhance affinity, perhaps 
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through potential hydrogen bonding with the receptor protein. The synthesis of an arylamino 
derivative was achieved as follows: 2-[(2-p-aminophenethyl)thio]-ATP, 15, was obtained 
quantitatively upon PtO2-catalyzed hydrogenolysis of the corresponding nitro compound, 
13, at room temperature overnight. An aliphatic amine congener, compound 19, was 
obtained in three steps from 2-thioadenosine, 25a (Figure 2), which was alkylated by 1,7-
dibromoheptane in a dilute NaOH solution. The product, 2-[(7-bromohepty1)-thio] 
adenosine, 31, was triphosphorylated to provide an alkylating intermediate, 32. This 
bromoalkyl triphosphate derivative was subsequently exposed to concentrated ammonia for 
3 hat room temperature, yielding the desired amino product, 19. Substitution of the bromide 
in compound 32 with hydrosulfide ion (addition of an excess of NaSH at room temperature 
for 20 h) gave rise to the thiol derivative, compound 20. Treatment of 32 with aqueous 
sodium thiocyanate provided compound 21.
On the basis of the above mentioned guidelines for the synthesis of a potentially potent and 
stable agonist, we also sought to enhance selectivity toward P2Y-receptors. The basis for the 
development of a third generation agonist was the finding that N6-alkyl substitution (e.g. 
methyl or etheno group bridging N1 and N6, see below and ref 27) caused loss of activity of 
the corresponding ATP agonist at P2X-receptors at ≤ 10 µM, but not at P2Y-receptors in the 
ileum or turkey erythrocytes. In light of the possibility that base-modification of ATP might 
yield P2Y-receptor agonists of very high potency and specificity we have begun a systematic 
analysis of the activity of 2- and N6-substitutions of the ATP molecule.
Thus, aiming at the synthesis of N6-methyl-ATP analogues, N6-methyladenosine, 25a, was 
N-oxidized using m-chloroperbenzoic acid in acetic acid (Figure 1), which we found to be 
more efficient than the hydrogen peroxide procedure.19 Introduction of a 2-thiol group was 
achieved in a two-step procedure: ring opening of the base-sensitive oxidized pyrimidine to 
the corresponding oxime by a short reflux in NaOH solution, followed by reaction with CS2, 
ring closure and N-oxide reduction, done under high temperature and pressure conditions.28 
N6-Methyl-2-thioadenosine, 27b, was alkylated by 1-hexen-6-yl bromide in DMF in the 
presence of Et3N at room temperature to provide 28b, which was phosphorylated to give rise 
to both triphosphate, 23, and monophosphate, 24, products in 30% and 34% yield, 
respectively.
P2Y-Purinoceptor-Mediated Activation of Phospholipase C
Turkey erythrocytes have been shown previously to express a P2-purinoceptor that markedly 
stimulates inositol lipid hydrolysis.11,12 This receptor has been tentatively identified as a 
P2Y-purinoceptor based on the high potency of 2-(methylthio)-ATP for stimulation of 
inositol phosphate accumulation and the low potency of agonists, i.e. α,β-MeATP and β,γ-
MeATP, that have been previously proposed to be potent P2X-receptor agonists. Similarly, 
UTP, which activates P2U-receptors, only weakly activated the avian erythrocyte receptor at 
relatively high concentrations.
Essentially no basal inositol phosphate activity was observed in membranes prepared from 
[3H]inositol-labeled turkey erythrocytes, and a very small stimulation was observed in the 
presence of 1 µM GTPγS (not shown). Addition of ATP resulted in a marked concentration-
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dependent activation of the erythrocyte phospholipase C11,12 as shown in Figure 3; this 
effect was absolutely dependent on the presence of guanine nucleotides (refs 11, 12 and data 
not shown). A broad range of analogues of ATP were equally efficacious to the parent 
compound. Moreover, two commercially available analogues, 2MeSATP, 6, and 2-chloro-
ATP, 5, were considerably more potent than ATP.
2-(Alkylthio)-substituted ATP analogues (compounds 8, 9, 12, 13, 15, 16, 17, 19, 20, and 
21) were tested for their capacity to stimulate inositol lipid hydrolysis in turkey erythrocyte 
membranes. Except for the 7-aminoheptyl and 7-thioheptyl derivatives, 19 and 20, 
respectively, these thioether derivatives were all at least 2 orders of magnitude more potent 
(K0.5 values = 5–30 nM) than ATP (Figure 3 and Table I). Thus, most of these compounds 
were more potent than 2-chloro-ATP, 5 (K0 5 = 72 nM). The thioether derivatives were also 
equiefficacious to ATP in the turkey erythrocyte membranes.
Although a detailed series of compounds is not yet available, N6-substitution, either of ATP 
itself (compound 22) or of a more potent 2-thioether (compound 23), did not markedly affect 
the apparent potency at the erythrocyte P2Y-receptor (Figure 4), although P2X-receptor 
activity was abolished (see below). Upon N6-methylation, the potencies of ATP (compound 
1 vs 22) and 2-(hexenylthio)-ATP (compound 9 vs 23) were diminished by only 7-fold and 
2.6-fold, respectively. Such hybrid substitutions may be the basis for the development of 
even more potent, selective P2Y-receptor agonists.
As described previously, the erythrocyte receptor was activated equally well by ATP and 
ADP and very potently by ADPβS. Moreover, as illustrated in Figure 4 and Table I, 
2MeSATP, 6 (K0.5 = 8 nM), was equipotent to 2-MeSADP (see Table I), 7 (K0.5 = 6 nM). 
This relationship also was observed for longer chain analogues, i.e. 2-(5-hexenylthio)-ATP, 
9 (K0.5 = 10 nM), was equipotent to 2-(5-hexenylthio)-ADP, 10 (K0.5 = 4 nM). Thus, 
triphosphates are not more potent activators of the erythrocyte P2Y-receptor than their 
corresponding ADP analogues.
AMP, 3, had practically no affinity for turkey erythrocyte P2Y-receptors. Curiously, the 
monophosphate 2-thioether analogues, such as 2-[(6-cyanohexyl)thio]-AMP, 18 (K0.5 = 37 
µM), were full agonists (Figure 6), although considerably less potent than the corresponding 
ATP analogues, 17. A 2-hexenylthio monophosphate derivative, compound 11, however, 
was only 33-fold less potent at turkey erythrocyte P2Y-receptors than the corresponding 
triphosphate. This enhancement of potency in adenine monophosphate derivatives 
containing long-chain 2-thioether groups was incompatable with the N6-methyl 
modification. Thus, N6-methyl-2-(hexenylthio)adenine monophosphate, compound 24 
(Figure 4), was nearly inactive. Several adenosine precursors (2-thioethers), of which the 5′-
phosphate derivatives were highly potent, [2-(5-hexenylthio)-and2-[(2-(4-
nitrophenyflethyl]-thio] adenosine, 28a and 30a, respectively] were found to be inactive in 
stimulating production of inositol phosphates at concentrations up to 100 µM.
A (2-phenylethyl)thio substituent (compound 12) has been substituted on the ring with a 4-
nitro (13) or a 4-amino group (15). Compound 15, which is also intended as a substrate for 
radioiodination, was extremely potent at turkey erythrocyte P2Y-receptors. A comparison of 
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functional group replacement at the distal carbon of a 2-thioheptyl chain (compounds 19, 20, 
and 21) reveals a wide variation in potency. At this position, an SCN or an NH2 group is 
favored over an SH group.
P2X- and P2Y-Receptor Smooth Muscle Assays
Pharmacological assays of P2Y-receptors included relaxation of the guinea pig taenia 
coli,29,30 endothelium-dependent relaxation of the rabbit aorta,21 and endothelium-
independent relaxation of the rabbit mesentericartery.31 Pharmacological assays at P2X-
receptors29,30,32 included contraction of the saphenous artery of the rabbit and contraction of 
the vas deferens and bladder of the guinea pig.
In the pharmacological P2Y-receptor assays, 2-thioether ATP derivatives (compounds 8, 9, 
12, 13, 15, 16, 17) were as potent or nearly as potent as 2MeSATP, with EC50 values with 
pD2 values in the range of 7–8 in the relaxation of guinea pig taenia coli (Table I). As in the 
turkey erythrocyte response system, 2-[(6-cyanohexyl)thio] AMP, 18, was a full agonist, 
although much less potent (curve not shown). The 2-hexylthio analogue, 8, was less potent 
than its corresponding unsaturated derivative, 2-(5-hexenylthio)-ATP, 9 (Figure 7). 
Curiously, two derivatives, 2-(2-phenylethyl)thio-, 12, and 2-(cyclohexylthio)-ATP, 16, had 
a greater efficacy than 2MeSATP in the mesenteric artery but less efficacy than 2MeSATP 
in the rabbit aorta.
In the 2-alkylthio series, the pD2 values were generally greater in the taenia coli than in the 
rabbit aorta or mesenteric artery. The largest enhancement in potency at the intestinal versus 
the vascular smooth muscle responses was seen with compound 16, the cyclohexylthio 
analogue, which was 63-fold more potent in the taenia coli than in the rabbit aorta, and with 
compound 17, the cyanohexylthio derivative, which was 79-fold more potent in the taenia 
coli than in the aorta. Other analogues were between 4- and 25- fold selective for the taenia 
coli receptor. In contrast, the cyclohexylthio derivative of AMP, compound 18, was 63-fold 
more potent in the mesenteric artery than on the taenia, although in this artery it had only 
approximately half the efficacy of 2MeSATP.
The 2-thio-substituted ATP analogues also were evaluated in pharmacological assays at 
P2X-receptors. As with 2-(methylthio)-ATP, 6, no activity was observed with compounds 8, 
9, 12, 16, and 22 in the contraction of the rabbit saphenous artery P2X-receptors, and other 
triphosphates had minimal activity. In this series, only moderate activity was seen at guinea 
pig vas deferens P2X-receptors, except for compounds 12, 13, and 17, which were very 
potent. At bladder P2X-receptors, only 2-[(phenylethyl)-thiol-ATP, 12, was very potent.
In smooth muscle assays, the agonist N6-methyl-ATP, 22, was selective for P2Y-receptors in 
the taenia coli, where it was approximately equipotent to ATP. In contrast, N6-methyl-ATP 
was inactive at P2X-receptors at ≤10 µM in all three tissues. On the basis of this observation, 
a hybrid molecule, 23, was synthesized, incorporating the N6-methyl modification 
(rendering P2Y-selectivity) and the long-chain thioether (rendering high potency at P2Y-
receptors). This compound was inactive at P2X-receptors at ≤10 µM but markedly stimulated 
smooth muscle P2Y-receptors at low concentrations. These data are consistent with the high 
potency of 23 for stimulation of turkey erythrocyte phospholipase C (Figure 4).
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On the basis of our results a series of high-affinity P2Y-purinoceptor agonists have been 
identified that are much less active or inactive at P2X-purinoceptors. A direct comparison of 
the relative potencies of these compounds in the phospholipase C assay to potencies at 
taenia coli test P2Y-receptors is presented in Figure 8. An r value of 0.96 was observed, 
suggesting that these two receptors are very similar. Although the potencies for these 
compounds at P2Y-purinoceptors in rabbit aorta and mesenteric artery were highly 
correlated, these potencies were not well correlated with the values for taenia coli or 
phospholipase C responses.
Discussion
The initial delineation of the P2Y-subclass of P2-purinoceptors principally was based on the 
selectivity of 2MeSATP for activation of these receptors and their relatively low affinity for 
α,β-MeATP and β,γ-MeATP. While this subclassification has largely held for P2Y-
purinoceptors in a broad range of target tissues and with several physiological and 
biochemical responses, the limitations accompanying the lack of receptor-selective agonists 
and antagonists have been considerable. Thus, neither the possibility of the existence of 
multiple P2Y-purinoceptors nor that of multiple PS-purinoceptor-promoted signaling 
mechanisms has been adequately addressed. Outside of avian erythrocyte preparations,15 the 
P2Y-purinoceptor(s) has not been radiolabeled, and only recently was structural information 
on the receptor published.36
The work described here gives new insight into the chemical features of ATP analogues that 
favor interaction with P2Y-purinoceptors and describes a series of compounds that should be 
useful for further characterization of P2Y-purinoceptors. By comparing the structural 
features for activation of P2Y-purinoceptors with those for activation of smooth muscle P2X-
purinoceptors, we have also identified drugs that exhibit high selectivity for interaction at 
P2Y-versus P2X-purinoceptors. On the basis of the limited structure—activity analyses for 
activation of P2T- and P2U-purinoceptors, it is unlikely that the high-affinity P2Y-
purinoceptor agonists studied here activate P2T- and P2U-receptors. For example, ATP, but 
not 2MeSATP, activates P2U-purinoceptors,16 and 2MeSADP, but not 2MeSATP, activates 
P2T-purinoceptors.22,23 We believe that there is a strong possibility that multiple P2Y-
purinoceptors exist, e.g. compare the activity of compound 16 at the turkey erythrocyte and 
rat aorta receptors, although the possibility of species differences in affinity at the same 
subtype has not been ruled out. Compound 14, on the other hand, is roughly equipotent at all 
of the P2Y-purinoceptors examined. Thus, various of these new high-affinity analogues may 
exhibit considerable differences in affinity for potential further subdivisions of the P2Y-
purinoceptor subtype. More unambiguously defined model systems or expression of cloned 
receptors36,37 and selective antagonists are needed to rigorously approach this question. For 
example, it is not known whether any one of the smooth muscle responses measured in this 
study involves the action of a single or multiple P2-purinoceptors. The differential activities 
of many analogues in the P2X-purinoceptor assays is suggestive of multiple subtypes. Thus, 
compound 12 was inactive in the rabbit saphenous artery and significantly more potent than 
ATP in both the guinea pig vas deferens and bladder.
Fischer et al. Page 7













The 2-(alkylthio)-ATP analogues, which are highly potent at P2Y-receptors, were previously 
shown to resist degradation by nucleotidases in brain membrane preparations.19 It is 
noteworthy that this is the first example of a structural change distal to the triphosphate 
group itself that renders the analogue stable. This stability is general, since it was apparent in 
the pharmacological assays in this study, and it will greatly enhance the utility of the 2-
thioethers as selective pharmacological tools. Since these compounds are of nanoraolar 
potency in turkey erythrocytes, they may serve as the basis for the design of molecular 
probes for ATP receptors. Such probes, potentially including radioligands, fluorescent 
probes, immobilized ligands for affinity chromatography, affinity labels, and covalently 
reactive ligands could be obtained using a functionalized congener approach, as has been 
demonstrated for other classes of purine receptors.20
In summary, we have synthesized a series of novel, long-chain derivatives of 2-
(methylthio)-ATP and found them to be of high potency at P2Y-purinoceptors, in some cases 
surpassing that of the parent compound 2-MeSATP. The most potent compounds in this 
study in the turkey erythrocytes (K0.5 ≤ nM) were 8, 9, 15, and 17 (triphosphates) and 7 and 
10 (diphosphates). There is a high correlation of their biological potencies in two different 
assays of P2Y-purinoceptor activity, stimulation of phospholipase C in turkey erthyrocytes 
and relaxation of the taenia coll. This possibly indicates a close similarity between these 
P2Y-purinoceptors. However the same compounds have different potencies at the P2Y-
receptors of rabbit aorta and mesenteric artery, suggesting that P2Y-purinoceptors in the 
vascular preparation represent a different subtype or that multiple receptors are involved. 
ATP 2-thioether analogues were active to varying degrees, depending on distal sub stituents 
of the thioether moiety, at P2X-receptors, in the guinea pig vas deferens and bladder. The 
conclusions of the structure–activity analysis are (1) N6-methyl modification contributes to 
selectivity at certain P2Y-receptors. N6-Methyl-ATP derivatives were appreciably active at 
P2Y-receptors in turkey erythrocytes or the taenia coil, but inactive in the rabbit mesenteric 
artery. This modification appears to be compatible with the long-chain, potency enhancing 
2-thioethers. (2) 2-Thioethers of ADP are equipotent with the ATP analogues in both 
biochemical and smooth muscle assays. (3) AMP itself is essentially inactive at P2-
purinoceptors (very weakly active in the taenia coli), but with the 2-thioether modification, 
the monophosphates become weak, but full agonists in turkey erythrocyte P2Y-




New compounds were characterized (and resonances assigned) by proton nuclear magnetic 
resonance using a Varian GEMINI-300 FT-NMR spectrometer. Nucleotides were 
characterized also by 31P NMR in D2O using H3PO4 as an external reference on a Varian-
ASM 100 300-MHz spectrometer. Samples (pD ranged from 5 to 7) were treated with 
CHELEX-100 (Bio-Rad, Richmond, CA) prior to spectral measurement. Synthetic 
intermediates and all final products were characterized on a Finnigan MAT mass 
spectrometer by chemical ionization mass spectrometry (NH3) and high-resolution mass 
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spectrometry. Nucleotides were desorbed from a glycerol matrix under FAB (fast atom 
bombardment) conditions using 6-kV Xe atoms on a JEOL SX102 spectrometer. N6-
Methyladenosine, 2MeSATP, 2MeSADP, and 2-chloro-ATP were obtained from Research 
Biochemicals, Inc. (Natick, MA). 2-Thioadenosine was the kind gift of Dr. Ray Olsson 
(Univ. So. Florida, Tampa, FL) or was synthesized as described.19 Purification of 
nucleotides was achieved on DEAE-A25 Sephadex columns as described below. Where 
needed final purification was done on a Hewlett-Packard 1090 HPLC system using a 
semipreparative SynChropak RP-P-100 column (1 × 25 cm, SynChrom, Inc., Lafayette, IN) 
and a linear gradient of a 0.1 M triethylammonium acetate buffer (TEAA, pH = 7) and 
acetonitrile (see below) with a flow rate of 3 mL/min ((triethylammonium)4 salt isolated). 
For analytical purposes, a nucleotide/nucleoside 7U column (250 mm × 4.6 mm, Alltech 
Associates, Inc., Deerfield IL) was used applying the same gradient as above at a 1 mL/min 
flow rate. The purity of the nucleotides described below was evaluated on an analytical 
column in two different solvent systems. One solvent system (I) was 0.1 M TEAA/CH3CN, 
80:20 to 40:60, in 20 min. The other (II) was 60 mM ammonium phoshphate and 5 mM 
tetrabutyl-ammonium phosphate (TBAP) in 90% water/10% methanol (A) and 5 mM TBAP 
in methanol (B). A concentration gradient from 25% B to 75% B in 8 min was applied. 
Peaks were detected by UV absorption at 260 nm using a diode array detector. ATP 
derivatives were generally >91% pure.
N6-Methyladenosine N1-Oxide (26b)
A solution of N6-methyladenosine (2 g, 6.7 mmol) and m-chloroperbenzoic acid (2.3 g, 13.4 
mmol) in acetic acid (20 mL) was stirred at room temperature for 2 days. Water (20 mL) 
was added to the reaction mixture, and a resulting thick precipitate was removed by filtration 
and discarded. The filtrate was coevaporated repeatedly with water under high vacuum, and 
the foamy residue was chromatographed on a silica gel column (CHCl3/MeOH, 2:1). The 
product was obtained as a white solid Imp 145 °C, crystallization from EtOH) in 45% yield 
(0.9 g). 1H NMR (DMSO): δ 8.62 (s, H-2), 8.55 (s, H-8), 5.88 (d, J = 5.4 Hz, 1H, H-1′), 4.51 
(“t”, J = 5.1 Hz, 1H, H-2′), 4.15 (“t”, J = 4.5 Hz, 1H, H-3′), 3.94 (AB q, 1H, H-4′), 3.61 (AB 
dq, J = 12, 4 Hz, 2H, H-5′), 3.46 (s, 3H, Me) ppm. MS (CI): m/e 298 (MH+). Anal. Calcd for 
C11H15N5O5: C, 40.12; H, 4.59; N, 21.29. Found: C, 40.44; H, 5.34; N, 20.29.
N6-Methyl-2-thioadenosine (27b)
Compound 26b was converted to 5-amino-1-β-D-ribofurazosylimiclazole 4-(N-methyl)-
carboxidoxime by the adaptation of the method of Kikugawa et al.25 and was obtained in a 
quantitative yield as a yellowish oil. 1H NMR (CD3OD): δ 8.54 (s, 1H, H-2), 7.46 (s, 1H, 
OH), 5.56 (d, J = 6.2 Hz, 1H, H-1′), 4.47 (t, J = 5.9, 1H, H-2′), 4.23 (dd, J = 5.6, 3.5 Hz, 1H, 
H-3′), 4.02 (dd, J = 6.0, 3.0 Hz, 1H, H-4′), 3.75 (AB dq, J = 12.0, 3.0 Hz, 2H, H-5′), 2.90 (a, 
3H, Me) ppm. 5-Amino-1-β-D-ribofuranosylimidazole 4-(N-methyl)carboxidoxime is 
thermally unstable and was used immediately or kept at −80 °C.
A heterogeneous solution of 5-amino-1-β-D-ribofuranosylimidazole 4-(N-
methyl)carbaxidoxime (0.7 g, 2.5 mmol) in MeOH/H2O/CS2 (19/7/5.5 mL, respectively) 
was heated in a sealed tube at 120 °C for 5 h. After cooling, the solution was evaporated to 
dryness and the brownish residue was chromatographed on a silica gel column (CHCl3/
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MeOH, 2:1, and then MeOH). Final purification was achieved by dissolution of the product 
in CHCl3/MeOH, 2:1, and then treatment with ether. The product, 27b, was obtained as a 
light yellowish solid (0.4 g, 51% yield, nip >230 °C, tritutated from ether). 1H NMR 
(CD3OD): δ 8.14 (s, 1H, H-8), 5.85 (d, J = 5.6 Hz, 1H, H-1′), 4.61 (“t”, J = 5.3 Hz, 1H, 
H-2′) 4.28 (dd, J = 5.2, 3.6 Hz, 1H, H-3′), 4.12 (“t”, 1H, H-4′), 3.81 (AB dq, J = 12.0, 2.5 
Hz, 2H, H-5′), 3.31 (s, 3H, Me) ppm. MS (CI): m/e 314 (MH+). High-resolution FAB 
(positive ions, glycerol matrix) calcd for C11H16N6O4S (MH+) 314.0923, found 314.0936.
2-(5-Hexenylthio)adenosine Itemileydrate (28a)
2-Thioadenosine (27a, 0.2 g, 0.67 mmol) was dissolved in 0.25 M NaOH (8 mL, 2 mmol). 
6-Bromo-1-hexene (0.45 mL, 3.3 mmol) was added, and the solution was stirred at room 
temperature for 3 h. The reaction mixture was concentrated under reduced pressure (bath 
temperature 33 °C) and extracted with ether (2 × 2 mL). The aqueous phase was neutralized 
with 18% HCl and extracted with ethyl acetate (3 × 4 mL). The homogeneous product was 
obtained after drying and solvent removal as a yellowish solid (0.14 g, 55% yield, mp 94 °C, 
trituration with ether). 1H NMR (CD3OD): δ 8.16 (s, 1H, H-8), 5.91 (d, J = 5.8 Hz, 1H, 
H-1′), 5.8 (dm, 1H, olefinic), 4.93 (ddd, J 11. 9.7, 1 Hz, 2H, olefinic), 4.72 (“t”, 1H, J = 5 
Hz, H-2′), 4.31 (m, 1H, H-3′), 4.11 (m, 1H, H-4′), 3.83 (m, 2H, H-5′), 3.16 (m, 2H, CH2S), 
2.10 (m, 2H, CH2), 1.74 (m, 2H, CH2), 1.56 (m, 2H, CH2) ppm. Anal. Calcd for 
C16H23N5O4S•0.5H2O: C, 49.22; H, 6.20; N, 17.93. Found: C, 49.46; H, 5.99; N, 17.36.
N6-Methyl-2-(5-hexenylthio)adenosine (28b) was prepared according to the same 
procedure for 28a in 23% yield (mp >230 °C dec) after column purification (CHCl3/MeOH, 
9:1) and trituration with ether. 1H NMR (CD3OD): δ characteristic N6-Me resonance at 3.1 
ppm (br s). HRMS: calcd for C17H24N5O4S 395.1611, found 395.1627.
General Nonaqueous Alkylation Procedure
A solution of 2-thioadenosine, 27a, or N6-methyl-2-thioadenosine, 27b (0.3 mmol), and dry 
Et3N (1.5 equiv) in dry dimethylformamide (2 mL) was stirred at room temperature for 0.5 
h. Alkyl bromide (5 equiv) was added and stirring continued for an additional 2.5 h. The 
reaction solution was cooled in an ice bath, and a small amount of water (ca. 1 mL) was 
added. The white precipitate was filtered, dried, and chromatographed on a silica gel column 
(CHCl3/MeOH, 5:1). Final purification was by precipitating the product from CHCl3/MeOH 
(5:1) solution upon treatment with ether.
2-(6-Cyanohexylthio)adeno s ine Hemi hyd rate (29a)
This compound was prepared according to the above nonaqueous procedure in 72% yield 
(97 mg). The product was obtained as a yellowish solid (mp 162 °C, crystallized from 
EtOH/H2O). 1H NMR (CD3OD): δ 8.17 (s, 1H, H-8), 5.92 (d, J = 5.9 Hz, 1H, H-1′), 4.72 (t, 
J = 5.6 Hz, 1H, H-2′), 4.31 (dd, J = 4.8, 3.5 Hz, 1H, H-3′), 4.11 (AB q, 1H, 11-4′), 3.79 (AB 
dq, J = 11.4, 2.9 Hz, 2H, H-5′). 2.44 (t, J = 6.9 Hz, 4H, CH2CH2), 1.76 (“t”, 2H, CH2), 1.65 
(“t”, 2H, CH2), 1.51 (m, 4H, CH2CH2) ppm. MS (CI): m/e 409 (ME+). Anal. Calcd for 
C17H24N6O4S• 0.5H2O: C, 48.91; H, 6.04; N, 20.13. Found: C, 48.94; H, 5.86; N, 19.99.
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This compound was prepared according to the above nonaqueous procedure in 73% yield 
(0.23 g). The product was obtained as a yellowish solid (mp 186 °C, crystallized from 
EtOH/H2O). 1H NMR (CD3OD): δ 8.21 (s, 1H, H-8), 8.16 (d, J = 8.6 Hz, 2H, Ar), 7.57 (d, J 
= 8.6 Hz, 2H, Ar), 5.98 (d, J = 5.9 Hz, 1H, H-1′), 4.68 (“t”, J = 5.5 Hz, 1H, H-2′), 4.30 (rid, 
J = 5.1, 3.4 Hz, 1H, H-3′), 4.12 (AB q, 1H, H-4′), 3.79 (AB dq, J = 12.3, 2.9 Hz, 2H, H-5′), 
3.43 (m, 2H, CH2Ar), 3.18 (t, 2H, CH2S) ppm. HRMS: calcd for C18H20N6O6 448.1148, 
found 448.1165.
Nucleoside 5′-Triphosphate (Compounds 8, 9, 12, 13, 16, 17)
The procedure for nucleoside 5′;-triphosphate synthesis was adapted from Kovacs and 
Ötvös23 and Moffat.24
Preparation of Tri-n-butylammonium Pyrophosphate Solution for Trip hosphate Synthesis
Sodium pyrophosphate decahydrate (6.69 g, 0.015 mol) in water (100 mL) was stirred at 
room temperature for 10 min until a clear solution was attained. The latter was passed 
through a column of activated Dowex 50WX-8 200 mesh, H+ form (40 mL of wet resin, 720 
mequiv).
The column was washed with deionized water until neutral. The column eluate was 
collected in a flask (250 mL) containing tri butyl= ine (7.14 mL, 0.03 mol) and EtOH (75 
mL) with stirring at 0 °C. The solution became cloudy during elution and became clear 
when all of the free amine was consumed. Lyophilization yielded a viscous oil. The latter 
was dissolved in EtOH and evaporated under high vacuum (bath temperature 35–40 °C). 
The process was repeated three times using dry dimethylformamide (30 mL) as the solvent, 
resulting in a thick oil which was dissolved in dry dimethylformamide (30 mL) and stored 
cold over activated molecular sieves.
Preparation of Triethylammoniutn Bicarbonate (TEAB) Buffer
A 1 M solution was prepared by adding dry ice to a 1 M triethylaraine solution in a flask 
covered tightly by a balloon far ca. 2 h until the pH reached 7.5.
General
All triphosphorylation reactions were carried out in a three-neck flask flame-dried under N2. 
Nucleosides and Proton Sponge (Aldrich Chemical Co., Milwaukee, WI) were dried 
overnight in a vacuum oven. Anhydrous solvents were used (trimethyl phosphate, 
dimethylformamide). Phosphorous oxychloride was distilled and kept under N2.
Typical Procedure
A solution of N6-methyl-2-(5-hexenylthio)adenosine (28b, 0.03 g, 0.076 mmol) and Proton 
Sponge (0.024 g, 1.5 equiv) in trimethyl phosphate (1 mL) was stirred for 10 min at 0 °C. 
Phosphorous oxychloride was added dropwise (14 µL, 0.152 mmol), and the clear solution 
was stirred for 2 hours at 0 °C. A mixture of Bu3N (75 µL) and 0.5 M (Bu3NH+)2 P2O7H2 in 
dimethylformamide (1 mL) was added at once. After 2 min 0.2 M TEAB solution (7.5 mL) 
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was added, and the clear solution was stirred at room temperature for 45 min. The latter was 
lyophilized overnight. TLC on a silica gel plate, using propanol/H2O/28% NH4OH (11:2:7) 
as the eluent, indicated the disappearance of starting material and the formation of a polar 
product (Rf = 0.3). The spot was typically intensely purple under UV light and dark brown in 
an I2 chamber. The semisolid obtained after lyophilization was chromatographed at room 
temperature on a Sephadex DEAE-A25 column, which was swelled in 1 M NaHCO3 in the 
cold for 3 days (7 × 1.5 cm). The resin was washed with de ionized water (75 mL), using a 
peristaltic pump, and loaded with the crude reaction residue dissolved in a minimal volume 
of water. The separation was monitored by UV detection (ISCO, UA-5) at 280 nm. A buffer 
gradient of 250 mL of water to 250 mL of 0.5 M NH4HCO3 was applied, and 90 5-mL 
fractions were collected. The relevant fractions were pooled and lyophilized twice to yield a 
white solid. N6-Methyl-2-(5-hexenylthio)adenosine monophosphate monoammonium salt 
(24) was obtained in 34% yield (13 mg). 1H NMR (D2O): δ 8.52 (s, 1H, H-8), 6.16 (d, J = 
5.4 Hz, 1H, H-1′), 5.80 (m, 1H, vinylic), 3.79 (s, 3H, Me), 2.13 (m, 2H, CH2), 1.79 (m, 2H, 
CH2), 1.56 (m, 2H, CH2). High-resolution FAB: calcd for C17H25N5SO7P 474.121, found 
474.1238 (M2− + 2H+). Retention time: 8.6 min (98% purity) using solvent system II. N6-
Methyl-2-(5-hexenylthio)adenosine 5′-triphosphate (23) eluted after the monophosphate and 
was obtained in 30% yield as the tetraammoniurn salt. 1H NMR (D2O): δ 8.34 (s, 1H, H-8), 
6.11 (d, J = 5.7 Hz. 1H, H-1′), 5.91 (m, 1H, vinylic), 5.05 (dd, J = 7.5, 1.6 Hz, vinylic), 4.98 
(dd, J = 10.4, 1.6 Hz, 1H, vinylic) (H-2′ is hidden by the water peak), 4.60 (t, J = 4.3 Hz, 
1H, H-3′), 4.38 (br.s, 1H, H-4′), 4.24 (m, 2H, H-5′), 3.23 (m, 2H, CH2S), 3.11 (s, 3H, Me), 
2.12 (q, J = 7 Hz, 2H, CH2), 1.78 (quintet, J =7 Hz, 2H, CH2), 1.56 (quintet, J = 7 Hz, 211, 
CH2). 31P NMR: δ −6.0 (br s), −10.9 (d), −21.6 (br s) ppm. High-resolution FAB: calcd for 
C17H27N5SO13P3 634.0539, found 634.0554 (M4− + 3H+). Retention time: 8.5 min (>98% 
purity) using solvent system I, 8.8 rain (>98% purity) using solvent system II.
2-(5-Hexenylthio)adenosine 5′-Diphosphate Trisammonium Salt (10)
The reaction was carried out on 0.158 mmol of nucleoside 28a following the typical 
procedure. In this reaction, however, 0.13 M (Bu3NH+)2PO4H in DMF (6.9 mL, 6 equiv) 
was used instead of bis(tributylammonium) pyrophosphate solution. TLC taken after workup 
(silica gel plate; solvent system propanol/28% NH4OH/H2O, 11:8:2) indicated the formation 
of three products (Rf = 0.33, 0.5, 0.7) in addition to a small amount of starting material. 
Separation on Sephadex DEAE-A25 column applying 0–0.5 M NH4HCO3 gradient (500 mL 
of each). Final separation was achieved on a semipreparative column applying a linear 
gradient of 0.1 M TEAA (pH 8.3)/CH3CN, 80:20 to 40:60 in 20 min (3 mL/min). Mono-, 
di-, and triphosphate products were obtained in 38% (29.7 mg), 30% (28 mg), and 5% (5.4 
mg), respectively. 1H NMR of 10 (D2O): δ 8.40 (s, 1H, H-8), 6.13 (d, J = 5.4 Hz, 1H, H-1′), 
4.62 (t, J = 4.7 Hz, 1H, H-3′), 4.37 (m, 1H, H-4′), 4.21 (m, 2H, H-5′) ppm. High resolution 
FAB: calcd for C16H24O10N5P2S 540.0719, found 540.0728. Retention time: 8.2 min (86% 
purity) using solvent system I, 7.4 min (86% purity) using solvent system II. NMR of other 
products: 2-(5-Hexenylthio)adenosine 5′-monophosphate diammonium salt (11). 11H NMR 
(D2O): δ 8.34 (s, 1H, H-8), 6.13 (d, J = 5.4 Hz, 1H, H-1), 5.91 (dm, 1H, olefinic), 5.01 (dd, J 
= 11, 9.7 Hz, olefinic), 4.50 (t, J = 4.5 Hz, 1H, H-3′), 4.37 (br s, 1H, H-4′), 4.13(m, 2H, 
H-5′), 3.21 (m, 2H, CH2S), 2.13 (q, J = 7 Hz, 2H, CH2), 1.77 (m, 2H, CH2), 1.55 (m, 2H, 
CH2) ppm. High-resolution FAB: calcd for C6H23O7N5PS: 460.1056. Found: 460.1052. 
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Retention time: 9.17 rain (>98% purity) using solvent system I, 7.43 min (>98% purity) 
using solvent system II. 2-(5-Hexenylthio)adenosine 5′-triphosphate tetraammonium salt 
(9). 1H NMR (D20): δ 8.41 (s, 1H, H-8), 6.13 (d, J = 5.7 Hz, 1H, H-1′), 4.64 (m, 1H, H-3′), 
4.37 (m, 1H, H-4′), 4.24 (dm, 2H, H-5′). High-resolution FAB: calcd for C16H25O13N5P3S 
620.0382, found 620.0428. Retention time: 7.7 min (91% purity) using solvent system I, 7.4 
min (>98% purity) using solvent system II. Compound 9 was also synthesized by the general 
triphosphorylation procedure above (19).
2-[2-(p-Nitrophenethyl)thiojadenosine 5′-triphosphate Tetraammonium Salt (13)
This compound was obtained as described above beginning with 0.1 mmol of nucleoside. 
Purification by ion exchange as above was achieved using a gradient of water and 0.6 M 
NH4HCO3 (230 mL of each). The triphosphate product 13 was obtained in 37% yield (27.6 
mg). 1H NMR (D2O): δ 8.33 (s, 1H, H-8), 7.97 (d, J = 8 Hz, 2H, Ar), 7.45 (d, J = 8 Hz, 2H, 
Ar), 6.02 (d, J = 5.9 Hz, 1H, H-1′) (H-2′ is hidden by the water peak), 4.60 (t, J = 4.2 Hz, 
1H, H-3′), 4.39 (br m, 1H, H-4′), 4.24 (br dm, 2H, H-5′), 3.50 (br m, 2H, CH2), 3.17 (br m, 
2H, CH2). 31P NMR (D2O, pD = 6): δ −7.07 (br s), −11.07 (d), −22.68 (br s) ppm. High-
resolution FAB: calcd for C18H23N6-O15,P3S 687.0082, found 687.0070 (MH3−). Retention 
time: 8.0 min (84% purity) using solvent system I, 7.3 min (98% purity) using solvent 
system II.
The monophosphate analog (14) was obtained in 35% yield (19.2 mg). 1H NMR (D2O): δ 
8.42 (s, 1H, H-8), 7.99 (d, J = 8.0 Hz, 2H, Ar), 7.49 (d, J = 8.0 Hz, 2H, Ar), 6.03 (d, J = 5.9 
Hz, 1H, H-1′), 4.50 (m, 1H, H-3′), 4.35 (m, 1H, H-4′), 4.00 (t, J = 4 Hz, 2H, H-5′), 3.57 (m, 
2H, CH2), 3.22 (m, 2H, CH2). High-resolution FAB: calcd for C18H20N6O9PS 527.0750, 
found 527.0738. Retention time: 9.6 min (95% purity) using solvent system I, 7.3 min (95% 
purity) using solvent system II.
2-[(2-p-Aminophenethyl)thio]adenosine 5′-Triphosphate Tetraammonium Salt (15)
Compound 13 (5 mg, 6.7 pmol) dissolved in 0.5 of mL H2O was hydrogenated overnight at 
room temperature (60 psi) over PtO2 catalyst. After removal of the catalyst by 
centrifugation, the product was purified by HPLC (retention time 6.5 min on a 
semipreparative column, using a linear gradient of TEAA/CH3CN 80:20 to 40:60 in 20 min) 
and obtained in a quantitative yield. 1H NMR (D2O): δ 8.34 (s, 1H, H-8), 7.14 (d, J = 8.3 
Hz, 2H, Ar), 6.77 (d, J = 8.3 Hz, 2H, Ar), 6.05 (d, J = 5.7 Hz, 1H, H-1′) (H-2′ is hidden by 
the water peak), 4.54 (t, J = 4.2 Hz, 1H, H-3′), 4.39 (br m, IH, H-4′, 4.24 (br dm, 2H, H-5′), 
3.40 (br m, 2H, CH2), 2.96 (br in, 2H, CH2). High-resolution FAB: calcd for 
C18H24N6O13P3S 657.0335, found 657.0323 (MH3−).
2-[(6-Cyanohexyl)thio]adenosine 5′-Triphosphate Tetraammonium Salt (17)
The reaction was carried out on 0.11 mmol of nucleoside 29a by the above procedure. A 
gradient of 0 to 0.5 M aqueous NH4HCO3 (generated from 230 mL of each) was applied 
during chromatography to obtain the product in 14% yield (10.7 mg). 1H NMR (D2O): δ 
8.48 (br s, 1H, H-8), 6.14 (d, J = 5.8 Hz, 1H, H-1′) (H-2′ is hidden by the water peak), 4.58 J 
= 4.3 Hz, 1H, H-3′, 4.39 (s, 1H, H-4′), 4.25 (br s 2H, H-5′), 3.22 (AB ddd, 2H, CH2S), 2.47 
(t, J = 7 Hz, 2H, CH2), 1.77 (t, J = 7 Hz, 2H,CH2) 1.66 (t, J = 7 Hz, 2H, CH2), 1.48 (n, 2H, 
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CH2) ppm. 31P NMR (D2O, pD = 5): δ −5.6 (d), −11.0 (d), −21.5 (t) ppm. High-resolution 
FAB: calcd for C17H26N6O13P3S 647.0491, found 647.00493 (M4− + 3H+). Retention time: 
6.0 min (91% purity) using solvent system I, 6.2 min (98% purity) using solvent system II.
The monophosphate analogue, 18, was obtained in 69% yield (39.6 mg). 1H NMR (D2O): δ 
8.46 (s, 1H, H-8), 6.12 (d, J = 6 Hz, 1H, H-1′), 4.51 (m, 1H, H-3′), 4.35 (m, IH, H-4′), 3.99 
(m, 2H, H-5′), 3.22 (ddd, J = 12.4, 5.9 Hz, 2H, CH2S), 2.47 (t, J = 7 Hz, 2H, CH2), 1.76 (m, 
2H, CH2), 1.66 (m, 2H, CH2), 1.48 (m, 4H, CH2CH2). 31P NMR (D2O, pD = 5): δ–7.4 ppm. 
High-resolution FAB: calcd for C17H24N6O7PS 487.1165, found 487.1148 (M2− + H+). 
Retention time: 4.9 min (85% purity) using solvent system I, 6.1 min (87% purity) using 
solvent system II.
2-[(7-Bromoheptyl)thio]adenosine (31)
2-Thioadenosine (27a, 0.2 g, 0.67 mmol) was dissolved in 0.25 M NaOH (8 mL, 2 mmol). 
1,7-Dibromoheptane (0.31 mL, 1.8 mmol) in EtOH (5 mL) was added, and the solution was 
stirred vigorously at room temperature for 3 h. The solution was concentrated in the rotary 
evaporator, and the remaining aqueous solution was extracted with ether (2 × 5 mL). The 
aqueous phase was neutralized with 1 M HCl. MeOH was added as a cosolvent followed by 
evaporation (2×). The yellowish residue was chromatographed on a silica column using 
CHCl3/MeOH, 5:1, as the eluent. The oily product was triturated with CHCl3/ether leaving a 
white solid (0.104 g, 33% yield, mp 137 °C). 1H NMR (CD3OD): δ 8.16 (s, 1H, H-8), 5.92 
(d, J = 5.7 Hz, 1H, H-1′), 4.72 (t, 1H, J = 5.6 Hz, H-2′), 4.31. (dd, J = 5.1, 1.5 Hz, 1H, H-3′), 
4 11 (dd, 1H, J = 6.3, 3.2 Hz, H-4′), 3.79 (AB dq, J = 12.4, 3 Hz, 2H, H-5′, 3.43 (t, J = 7 Hz, 
2H, CH2Br), 3.15 (m, 2H, CH2S), 1.74 (m, 4H, (CH2)2), 1.46 (m, 6H, (CH2)3) ppm. FAB 
(positive ions, glycerol matrix): 476, 478 (M + 1). Anal. Calcd for C17H26N5O4SBr: C, 
42.86; H, 5.50; N, 14.70. Found: C, 42.97; H, 5.52; N, 14.64.
2-[(7-Bromoheptyl)thiojadenosine 5′-Triphosphate Tetraammonium Salt (32)
The reaction was carried out on 0.11 mmol of nucleoside 31 following the typical procedure. 
A TLC taken after concentrating the crude reaction mixture by lyophilization indicated the 
formation of product (silica gel, propano1/28% NH4OH/H2O, 11:8:2, Rf = 0.45) in almost 
quantitative yield. A gradient of 0 to 0.75 M aqueous NH4HCO3 (generated from 500 mL of 
each) was applied during chromatography to obtain the product in 68% yield (53.2 mg). 1H 
NMR (D2O): δ 8.37 (br s, 1H, H-8), 6.11 (d, J = 5.7 Hz, 1H, H-1′), 4.75 (br “t”, 1H, H-2′), 
4.56 (br “t”, 1H, H-3′), 4.37 (br s, IH, H-4′), 4.22 (br s, 2H, H-5′), 3.44 (t, J = 7 Hz, 2H, 
CH2Br), 3.18 (m, 2H, CH2S), 1.75 (m, 4H, (CH2)2), 1.36 (m, 6H, (CH2)3) ppm. High-
resolution FAB: calcd for C17H28N5O13BrP3S 713.9801, 715.9782, found 713.9787, 
715.9807 (MH3−). Retention time: 13.2 min (>98% purity) using solvent system I, 9.3 min 
using solvent system II.
2[(7-Aminoheptyl)thiojadenosine 5′-Triphosphate Tetrakis(triethylammonium salt) (19)
Compound 32 (8.1 mg, 10 µmol) was dissolved in 28% NH4OH (0.5 mL) and stirred at 
room temperature for 3 h. The crude mixture was separated on a semipreparative HPLC 
column (retention time: 7.9 min using a linear gradient of TEAA/CH3CN, 95:5 to 40:60 in 
20 min). The product was obtained in 52% yield (5.6 mg) after repeated lyophilizations. 1H 
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NMR (D2O): δ 8.35 (s, 1H, H-8), 6.11 (d, J = 5.4 Hz, 1H, H-1′) (H-2′ is hidden by the water 
peak), 4.58 (br s, J = 5.4 Hz, 1H, H-3′), 4.40 (br s, 1H, H-4′), 4.24 (br s, 2H, H-5′), 3.21 (q, 
26H, CH2S + Et3N), 2.94 (t, J = 7 Hz, 2H, CH2NH2), 1.75 (t, J = 7 Hz, 2H, CH2), 1.62 (m, 
2H, CH2), 1.28 (t, J = 7 Hz, 42H, (CH2)3 + Et3N) ppm. High-resolution FAB: calcd for 
C17H30-N6O13P3S 651.0804, found 651.0778 (MH3−). Retention time: 7.9 min (94% purity) 
using 0.1 M TEAA/CH3CN, 95:5 to 40:60 in 20 rain, 5.1 min (87% purity) using solvent 
system II.
2-[(7-Thioheptyl)thioiadenosine 5′-Triphosphate Tetrakis(triethylammonium salt) (20)
Compound 32 (2 mg, 2.5 µmol) was dissolved in a concentrated solution of NaSH (12 mg, 
in 0.3 mL H2O) and stirred at room temperature for 20 h. The crude mixture was separated 
on a semipreparative HPLC column, retention time: 13.0 min using a linear gradient of 
TEAA (pH 8.4)/CH3CN, 80:20 to 40:60 in 20 min. The product was obtained in 60% yield 
(1.7 mg) after repeated lyophilizations. 1H NMR (D2O): δ 8.35 (s, 1H, H-8), 6.11 (d, J = 5.4 
Hz, 1H, H-1′), 4.61 (t, J = 5.4 Hz, 1H, H-3′), 4.37 (br t, 1H, H-4′), 4.24 (br AB q, 2H, H-5′), 
3.20 (br s, 28H, CH2S + Et3), 2.62 (t, J = 7 Hz, 2H, CH2-SH), 1.64 and 1.55 (each: m, 2H, 
CH2), 1.28 (br.s, 42H, (CH2)3 + Et3) ppm. High-resolution FAB: calcd for 
C17H29N5O13P3S2 668.0416, found 668.0421 (MH3−).
2-[(7-Thiocyanatoheptyl)thio]adenosine 5′-Triphosphate Tris(triethylammonium salt) (21)
Compound 32 (2 mg, 2.5 µmol) was dissolved in a concentrated solution of KSCN (20 mg, 
~100 equiv in 0.3 mL of H2O). The solution was stirred at room temperature for 20 h. The 
crude reaction mixture was separated on a semipreparative HPLC column. The product was 
obtained in 48% yield (1.2 mg) after three sequential lyophilizations.1H NMR (D2O): δ 8.40 
(s, 1H, H-8), 6.13 (d, J = 5.3 Hz, 1H, H-1′), 4.62 (br “t”, 1H, H-3′), 4.39 (br s, 1H, H-4′), 
4.24 (m, 2H, H-5′), 3.20 (q, J = 7 Hz, 18H, Et3), 3.02 (m, 2H, CH2S), 1.77 (m, 5H, CH2), 
1.43 (m, 7H, CH2), 1.28 (t, J = 7 Hz, 27H, Et3) ppm. High-resolution FAB: calcd for 
C18H28N6O13P3S2 693.0369, found 693.0358. Retention time: 7.7 min (>98% purity) using 
solvent system I.
Biological Assays
Stimulation of inositol phosphate formation by ATP analogues was measured in turkey 
erythrocyte membranes as described.11,12 The K0.5 values were averaged from three to eight 
independently determined dose–response curves for each compound. Briefly, 1 mL of 
washed turkey erythrocytes was incubated in inositol-free medium (DMEM; Gibco) with 
0.5–1 mCi of 2-[3H] myo-inositol (20 Ci/mmol; American Radiolabelled Chemicals Inc.) for 
18–24 h in a humidified atmosphere of 95% air 5% CO2 at 37 °C. Erythrocyte ghosts were 
prepared by rapid lysis in hypotonic buffer (5 mM sodium phosphate, pH 7.4, 5 mM MgCl2, 
1 mM EGTA) as described.12 Phospholipase C activity was measured in 25 µL of 
[3H]inositol-labeled ghosts (≈175 µg of protein, 200–500 000 cpm/assay) in a medium 
containing 424 µM CaCl2, 0.91 mM MgSO4, 2 mM EGTA, 115 mM KCl, 5 mM KH2PO4, 
and 10 mM Hepes, pH 7.0. Assay (100 µL final volume) contained 1µM GTPγS and the 
indicated concentrations of nucleotide analogues. Ghosts were incubated at 30 °C for 5 min, 
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and total [3H]inositol phosphates were quantitated by anion exchange chromatography as 
previously described.11,12
Relaxation of the carbachol-contracted guinea pig taenia coli, rabbit aorta, and rabbit 
mesenteric artery were measured as described.30,31,35 Muscle segments were mounted in 
organ baths at 37 °C and bathed in oxygenated Krebs solution, and changes in tension in 
response to increasing concentrations of nucleotide analogues were recorded (at least two 
determinations). Similarly contraction of the guinea pig isolated urinary bladder detrussor 
muscle, guinea pig vas deferens, and rabbit saphenous artery was measured as 
described.30,31,34
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FAB fast atom bombardment (mass spectroscopy)
HPLC high-pressure liquid chromatography
HRMS high resolution mass spectroscopy





TLC thin layer chromatography
EGTA 1,2-bis(2-aminoethoxy)ethane-N,N,N′,N′-tetraacetic acid
GTPγS guanosine-5′-O-thiotriphosphate
Hepes N-(2-hyd roxyethyl)piperazine-N′-(2-ethanesulfonic acid).
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Synthesis of 2-thioether and N6-methyl-ATP analogues. Compound a in this scheme (25–
30) refers to R = H, and compound b refers to R = CH3. Compound 27a was synthesized by 
procedures previously described.13,25 Conditions were: (i) m-chloroperbenzoic acid, 3 days, 
room temperature; (ii) (1) 5 N NaOH, (2) CS2, MeOH, H2O,120 °C; (iii) RBr, Et3N, DMF; 
(iv) (1) POCl3, (2) (Bu3NH+)2P2O7H2; (v) (1) POCl3, (2) (Bu3NH+)2-PO4H2. Adenine 5′-
triphosphate derivatives synthesized by this method but not shown in figure: 2-(hexylthio)-, 
8; 2[(2-phenylethyl)thio]-, 12; and 2-(cyclohexylthio)-, 16. Adenine 5′-monophosphate 
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derivatives also isolated as byproducts of the phosphorylation reactions: 2-(hexenylthio)-, 
11; 2-[[2-nitrophenypethyl]thio]-, 14; 2-(6-cyanohexylthio)-, 18; and 2-(6-cyanohexylthio)-
N6-methyl-, 24.
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Synthesis of terminally functionalized 2-(alkylthio)-ATP analogues, compounds 19–21.
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Concentration-dependent stimulation of inositol phosphate formation by 2-thioether 
derivatives of ATP. Membranes from [3H]inositol-labeled erythrocytes were incubated for 5 
min at 30 °C in the presence of the indicated concentrations of ATP, 1 (■); 2-(methylthio)-
ATP, 6 (○); 2-(hexylthio)-ATP, 8 (△); 2-(hexenylthio)-ATP, 9 (□); 2-[(phenylethyl)thio]-
ATP, 12 (◊); 2-(cyclohexylthio)-ATP, 16 (▽); 2-[(cyanohexyl)thio]-ATP, 17 (●); or 2-[[(p-
nitrophenyl)ethyl]thio]-ATP, 13 (▲). Incubation was in the presence of 1µM GTPγS as 
described in Materials and Methods. The data shown are the average of three to eight 
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experiments carried out in duplicate using different membrane preparations. The average 
cpm of [3H]inositol phosphates produced in the presence of 1 µM GTPγS alone was 400 
cpm (0%). The maximal (100%) level of [3H]inositol phosphates in the presence of GTPγS 
and adenine nucleotide analogues was at least 5000 cpm with all membrane preparations 
tested.
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Concentration-dependent stimulation of inositol phosphate formation by N6- and 2-thioether 
derivatives of ATP. Membranes from [3H]inositol-labeled erythrocytes were incubated in 
the presence of ATP, 1 (○); N6-methyl-ATP, 22 (●); 2-(hexenylthio)-ATP, 9 (△); N6-
methyl-2-(hexenylthio)-ATP, 23 (▲); and N6-methyl-2-(hexenylthio)-AMP, 24 (□). 
Incubation was for 5 min at 30 °C in the presence of 1 µM GTPγS. Data shown are from a 
representative experiment repeated at least three times with similar results. [3H] Inositol 
phosphate accumulation in the presence of 1µM GTPγS alone was 250 cpm (0%). Maximal 
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levels (100%) of [3H]inositol phosphate accumulation in the presence of GTPγS and a 
maximal concentration of N6-methyl-2-(hexenylthio)-ATP was 9150 cpm.
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Phospholipase C activity of 2-thioether analogues of ATP and ADP. Membranes from 
[3H]inositol-labeled erythrocytes were incubated in the presence of the indicated 
concentrations of ADP, 2 (■); ATP, 1 (□); 2-(methylthio)-ADP, 7 (●); 2-(methylthio)-ATP, 
6 (○); 2-(hexenylthio)-ADP, 10 (▲); or 2-(hexenylthio)-ATP, 9 (△). Incubation was for 5 
min at 30 °C in the presence of 1 µM GTPγS as described under Materials and Methods. The 
data shown are from a representative experiment repeated at least three times using different 
membrane preparations. [3H]Inositol phosphate accumulation in the presence of GTPγS 
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alone was 200–400 cpm (0%). Maximal levels of [3H) inositol phosphates produced by ADP 
and ATP analogues in the presence of GTPγS (100%) were identical within the same 
membrane preparation with values ranging from 5000 to 9000 cpm.
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Comparative effects of 2-thioether analogues of AMP and ATP on phospholipase C activity 
in turkey erythrocyte membranes. Membranes from [3H]inositol-labeled erythrocytes were 
incubated for 5 min at 30 °C in the presence of the indicated concentrations of AMP, 3 (□); 
ATP, 1 (■); 2-[(cyanohexyl)thio]-AMP, 18 (○); 2-[(cyanohexyl)thio]-ATP, 17 (●); 2-[[(p-
nitrophenyl)ethyl]thiol]-AMP, 14 (△); 2-[[(p-nitrophenyl)ethyl]thio]-ATP, 14 (▲). 
Incubation was in the presence of 1µM GTPγS as described under Materials and Methods. 
Results shown are from a representative experiment repeated at least three times using 
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different membrane preparations. [3H]inositol phosphate accumulation in the presence of 
1µM GTPγS alone was 200 cpm (0%). Maximal levels (100%) of [3H] inositol phosphate 
accumulation in the presence of GTPγS and a maximal concentration of agonist, e.g. 1µM 2-
[(cyanohexyl)thio]-ATP, was 6000 cpm.
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Concentration—response relationships for ATP and its derivatives causing relaxation of the 
carbachol-contracted guinea pig taenia coli (P2Y-purinoceptor). All curves are the mean of 
two determinations except for 1 (n = 38), 8 (n = 4), 11 (n = 3), and 14 (n = 5). ATP was 
tested on all the preparations that the derivatives were tested on. Ordinate axis shows the 
percentage relaxation of the carbachol-induced contraction; abscissa axis shows 
−log[agonist]. The pD2 value for 2MeSATP is 8.0 ± 0.15 (ref 33).
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Correlation between turkey erythrocyte P2Y-purinoceptor agonism and guinea pig taenia coli 
P2Y-purinoceptor agonism, represented by pK0.5 and pD2 values, respectively. The line 
shows the linear regression of pD2 on pK0.5, which had a correlation coefficient, r, of 0.960 
(P < 0.001) for the equation y = 0.5x + 3.59. None of these compounds had significant 
activity at P2X-purinoceptors (see Table I). The pD2 value for 2-(methylthio)-ATP 
(2MeSATP) was taken from the literature.24
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